Alfalight introduces new 25-watt pump module
The CPM-II is available with 25 watts of output power and a 200-micron (0.22 NA) output fiber for fiber laser applications. A version with 21 watts in a 6+1:1 pump/signal con...Alfalight awarded $1.7M from Army Research Lab
With the funding, Alfalight will develop pump modules suitable for pumping high-power, fiber-laser sys...Alfalight receives $4.7M to produce next generation lasers
The goal of the 18-month project, announced Tuesday, is to produce a multi-kilowatt diode laser system for industrial and military applications. The fund...Nair joins Alfalight; Prill coming to Journal Sentinel interactive media
as vice president of operations. Nair will lead Alfalight's production and engineering teams. He has nearly 20 years of experience in high-volume, high-quality semiconductor manufacturing. Prior to joining Alfalight, he was executive director of wafer fabrication at Maxim Integrated Products and ea...Alfalight receives $7 million in expansion funding
The financing package was led by GF Private Equity Group, LLC and included all of major previous investors. Those inclu...Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- AlfacellCorporation today announced that Lawrence A. Kenyon, executive vicepresident, chief financial officer and corporate secretary, willpresent an overview of the company's product development programsat 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York. The aud...Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
OSS, the Netherlands, June 27, 2007-Organon, the humanhealthcare business unit of Akzo Nobel, announced today that twoout of three Phase III clinical trials with corifollitropin alfa(Org 36286), a new long-acting fertility hormone, have reachedtheir randomization target. Corifollitropin alfa is a new recombinant fertility hormone. It isthe first of a new class of gonadotropi...SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
-- Data Presented at Annual Meeting of the American Society ofClinical Oncology -- SAN MATEO, Calif. -- June 4, 2007 -- SciClone Pharmaceuticals,Inc. (Nasdaq:SCLN) and Sigma-Tau S.p.A today announced thatSciClone's lead product candidate thymalfasin (ZADAXIN(r), thymosinalpha 1) achieved its primary endpoint in a phase 2 clinical trialtreating patients diagnosed with stage IV malig...